Cellectis Net Worth
Cellectis Net Worth Breakdown | CLLS |
Cellectis Net Worth Analysis
Cellectis' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cellectis' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cellectis' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cellectis' net worth analysis. One common approach is to calculate Cellectis' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cellectis' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cellectis' net worth. This approach calculates the present value of Cellectis' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cellectis' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cellectis' net worth. This involves comparing Cellectis' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cellectis' net worth relative to its peers.
Enterprise Value |
|
To determine if Cellectis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cellectis' net worth research are outlined below:
| Cellectis SA had very high historical volatility over the last 90 days | |
| Cellectis SA may become a speculative penny stock | |
| Cellectis SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 755 K. Net Loss for the year was (116.83 M) with profit before overhead, payroll, taxes, and interest of 35.3 M. | |
| Cellectis SA currently holds about 153.13 M in cash with (24.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Short Interest in Cellectis S.A. Expands By 59.7 |
Cellectis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cellectis SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cellectis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cellectis' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cellectis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectis SA backward and forwards among themselves. Cellectis' institutional investor refers to the entity that pools money to purchase Cellectis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Affirmative Financial Network | 2024-12-31 | 25.9 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 18.4 K | Baird Financial Group, Inc. | 2024-09-30 | 15.1 K | Xtx Topco Ltd | 2024-09-30 | 13.1 K | Susquehanna International Group, Llp | 2024-09-30 | 13 K | Wells Fargo & Co | 2024-09-30 | 12.1 K | Geode Capital Management, Llc | 2024-09-30 | 10.8 K | Harbour Investments, Inc. | 2024-09-30 | 6.1 K | Rhumbline Advisers | 2024-09-30 | 3.9 K | Long Focus Capital Management, Llc | 2024-09-30 | 4.6 M | Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 1.8 M |
Follow Cellectis' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 161.15 M.Market Cap |
|
Project Cellectis' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (1.07) | (1.13) |
When accessing Cellectis' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cellectis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cellectis' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cellectis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cellectis SA. Check Cellectis' Beneish M Score to see the likelihood of Cellectis' management manipulating its earnings.
Evaluate Cellectis' management efficiency
Cellectis SA has return on total asset (ROA) of (0.1609) % which means that it has lost $0.1609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.822) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to drop to -0.51 in 2025. At this time, Cellectis' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 9.4 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (1.1 K).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.45 | 1.38 | |
| Tangible Book Value Per Share | 1.44 | 1.36 | |
| Enterprise Value Over EBITDA | (1.06) | (1.11) | |
| Price Book Value Ratio | 2.18 | 3.61 | |
| Enterprise Value Multiple | (1.06) | (1.11) | |
| Price Fair Value | 2.18 | 3.61 | |
| Enterprise Value | 97.8 M | 92.9 M |
The decision-making processes within Cellectis are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 3.7406 | Revenue | Quarterly Revenue Growth 9.98 | Revenue Per Share | Return On Equity |
Cellectis Earnings per Share Projection vs Actual
Cellectis Corporate Management
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Kyung NamWortman | Executive Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.